Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
KORU Medical Systems designs and manufactures subcutaneous infusion devices, primarily the Freedom Integrated Infusion System for immunoglobulin (Ig) therapy delivery in home and alternate care settings. The company operates in a niche medical device market serving chronic immune deficiency patients, competing against traditional IV infusion and other subcutaneous delivery systems. Revenue growth is driven by expanding adoption of subcutaneous immunoglobulin (SCIG) therapy and recurring consumable sales from its installed base.
KORU operates a razor-razorblade model where initial pump placements generate ongoing consumable revenue. The Freedom system enables patients to self-administer subcutaneous immunoglobulin therapy at home rather than in clinical settings, reducing healthcare system costs. Pricing power derives from switching costs once patients are trained on the system, physician preference, and integration with specialty pharmacy distribution networks. Gross margins of 63% reflect favorable consumable mix, though operating losses indicate the company is still scaling to profitability. Revenue growth of 18% suggests market penetration is accelerating as SCIG adoption increases versus traditional IVIG therapy.
Quarterly pump placement volumes and installed base growth - directly drives future consumable revenue
Consumable utilization rates per patient - indicates therapy adherence and recurring revenue stability
New specialty pharmacy partnerships and distribution agreements - expands market access
Regulatory approvals for new indications or international markets - opens addressable market
Path to profitability milestones - cash burn rate and timeline to positive operating cash flow
Reimbursement policy changes - CMS or commercial payer decisions on home infusion coverage rates could materially impact economics and adoption
Competitive technology displacement - alternative subcutaneous delivery systems, wearable pumps, or novel immunoglobulin formulations could erode market share
Regulatory pathway complexity - FDA requirements for device modifications or new indications create development timeline and cost uncertainty
Larger medical device competitors (Baxter, Fresenius Kabi) entering subcutaneous infusion market with superior distribution and R&D resources
Specialty pharmacy consolidation reducing negotiating leverage and potentially favoring competitors with broader product portfolios
Direct-to-patient models from immunoglobulin manufacturers bypassing third-party infusion device providers
Negative operating cash flow and free cash flow create equity dilution risk if additional capital raises are needed before reaching profitability
Small market cap of $200M limits institutional investor base and creates liquidity risk during market stress
High price-to-sales of 5.5x leaves limited valuation cushion if growth disappoints or path to profitability extends
low - Immunoglobulin therapy for primary immunodeficiency and chronic inflammatory conditions is medically necessary and non-discretionary. Patient volumes are driven by diagnosis rates and clinical protocols rather than economic conditions. However, healthcare system budget pressures during recessions could slow adoption of home infusion programs versus traditional clinical settings.
Rising rates create moderate headwinds through two channels: (1) higher discount rates compress valuation multiples for unprofitable growth companies trading on forward earnings, and (2) increased financing costs if the company needs to raise capital given negative free cash flow. The 2.48x current ratio provides liquidity buffer, but sustained losses may require future capital raises at dilutive terms in high-rate environments.
Minimal direct credit exposure. The company sells primarily through specialty pharmacies and distributors with established payment terms. Patient reimbursement comes predominantly from commercial insurance and Medicare/Medicaid, providing stable payment streams. Low debt-to-equity of 0.22 indicates limited refinancing risk.
growth - Small-cap healthcare investors seeking exposure to home healthcare shift and recurring revenue models. The 18% revenue growth, improving net income trajectory (56% YoY improvement), and razor-razorblade business model appeal to growth-at-reasonable-price investors willing to accept near-term losses for long-term margin expansion potential. Not suitable for value or income investors given negative profitability and no dividend.
high - Micro-cap healthcare stock with $200M market cap exhibits elevated volatility from low trading liquidity, binary regulatory/reimbursement events, and quarterly earnings sensitivity. Small revenue base means individual contract wins or losses create outsized percentage impacts. Limited analyst coverage and institutional ownership amplify price swings.
